Blockchain Registration Transaction Record

Nutriband Secures FDA Meeting for Abuse-Deterrent Fentanyl Patch Technology

Nutriband Inc. secures FDA meeting for AVERSA abuse-deterrent fentanyl patch technology, addressing opioid crisis through innovative transdermal pharmaceutical development.

This development matters because it addresses the critical opioid crisis by introducing technology that could significantly reduce fentanyl abuse and accidental exposures. Fentanyl is responsible for the majority of opioid overdose deaths, and an abuse-deterrent patch could save countless lives while allowing legitimate pain patients to access necessary medication safely. The FDA's engagement signals recognition of the technology's potential impact on public health, potentially leading to faster regulatory approval and widespread adoption in medical practice.